ESO-T01 delivers its first four multiple myeloma case reports.
ApexOnco Front Page
Recent articles
Weeks after criticising the group’s big pharma partner, John Houston is on his way out.
The US subsidiary of South Korea’s HLB will take on the selective FGFR2 inhibitor.
Phase 3 development plans for BNT327 and ivonescimab start to diverge.
The company reports an “unprecedented” 100% PSA50 rate with JANX007, but in a small, selected number of patients.
Autolous, Syndax, Jazz and Shorla get US approvals in a quiet month.
Amid a KRAS data dump, a doublet of RMC-6236 and RMC-6291 was a highlight.
Myelofibrosis projects and Merck's ROR1 ADC fight for attention at this month's conference.
